Clinical efficacy and safety of buyang huanwu decoction for acute ischemic stroke: a systematic review and meta-analysis of 19 randomized controlled trials.
Clinical efficacy and safety of buyang huanwu decoction for acute ischemic stroke: a systematic review and meta-analysis of 19 randomized controlled trials.
复制标题
补阳还五汤治疗急性缺血性中风的临床疗效和安全性：19项随机对照试验的系统评价和荟萃分析
DOI：
10.1155/2012/630124
复制
发表时间：
2012
期刊：
影响因子：
--
通讯作者：
Zheng GQ
中科院分区：
文献类型：
--
作者：
Hao CZ;Wu F;Shen J;Lu L;Fu DL;Liao WJ;Zheng GQ
补阳还五汤是治疗中风致残的著名中药方剂。本研究的目的是评价补阳还五汤治疗急性缺血性脑卒中的有效性和安全性。截至2012年2月，在6个数据库中进行了系统性文献检索。纳入了评价补阳还五汤治疗急性缺血性卒中疗效和安全性的随机对照临床试验（RCT）。确定了19项RCT，共1580例受试者。这些研究的方法质量普遍较低。只有一项试验将死亡或依赖性作为主要结局指标。只有4项试验报告了不良事件。Meta分析显示，补阳还五汤改善神经功能缺损的临床有效率优于西药，P < 0.001。补阳还五汤治疗组与西药对照组神经功能缺损评分比较，差异有显著性意义（P < 0.001）。结论：补阳还五汤可改善急性缺血性脑卒中患者的神经功能缺损，且总体上是安全的。然而，由于纳入研究的方法学质量差和缺乏足够的安全性数据，目前的证据不足以支持BHD常规用于急性缺血性卒中。需要进一步严格设计试验。
Buyang Huanwu Decoction (BHD) is a well-known traditional Chinese herbal prescription for treating stroke-induced disability. The objective of this study was to evaluate the efficacy and safety of BHD for acute ischemic stroke. A systematic literature search was performed in 6 databases until February 2012. Randomized controlled clinical trials (RCTs) that evaluate efficacy and safety of BHD for acute ischemic stroke were included. Nineteen RCTs with 1580 individuals were identified. The studies were generally of low methodological quality. Only one of the trial included death or dependency as a primary outcome measure. Only 4 trials reported adverse events. Meta-analysis showed the clinical effective rate of neurological deficit improvement favoring BHD when compared with western conventional medicines (WCM), P < 0.001. There is significant difference in the neurologic deficit score between the BHD treatment group and the WCM control group, P < 0.001. In Conclusion, BHD appears to improve neurological deficit and seems generally safe in patients with acute ischemic stroke. However, the current evidence is insufficient to support a routine use of BHD for acute ischemic stroke due to the poor methodological quality and lack of adequate safety data of the included studies. Further rigorously designed trials are required.
登录
查看更多内容
影响因子：
3
作者：
Furlan, Andrea D.;Pennick, Victoria;van Tulder, Maurits
通讯作者：
van Tulder, Maurits
影响因子：
7.2
作者：
Guyatt, Gordon H.;Oxman, Andrew D.;Schuenemann, Holger J.
通讯作者：
Schuenemann, Holger J.
影响因子：
7.2
作者：
Balshem, Howard;Helfand, Mark;Guyatt, Gordon H.
通讯作者：
Guyatt, Gordon H.
影响因子：
5.4
作者：
Cai, Guangxian;Liu, Baiyan;Shen, Jiangang
通讯作者：
Shen, Jiangang
影响因子：
5.7
作者：
Chen, YS;Cheng, WC;Tsai, C
通讯作者：
Tsai, C